Activity of Cefepime in Combination with the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in <i>In Vitro</i> Checkerboard Assays
Wendy Kloezen, Ria J. B. Melchers, Panagiota‐Christina Georgiou, Johan W. Mouton, Joseph Meletiadis
Abstract
Extended-spectrum-β-lactamase (ESBL)-producing strains are increasing worldwide, limiting therapeutic options. Taniborbactam (VNRX-5133) is a newly developed β-lactamase inhibitor with a wide spectrum of activity covering both serine and metallo enzymes.
Topics & Concepts
CefepimeCheckerboardIn vitroMicrobiologyLimitingChemistryBiologyAntibioticsBiochemistryAntibiotic resistanceImipenemEngineeringMechanical engineeringAntibiotic Resistance in BacteriaTuberculosis Research and EpidemiologyPharmaceutical and Antibiotic Environmental Impacts